Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

by Inzucchi, Silvio E , Kitakaze, Masafumi , Langkilde, Anna-Maria , Howlett, Jonathan G , Dukát, Andrej , O’Meara, Eileen , Jhund, Pardeep S , Tereshchenko, Sergey , Drozdz, Jaroslaw , McMurray, John J.V , Held, Claes , Vinh, Pham N , Petrie, Mark C , Anand, Inder S , Solomon, Scott D , Schou, Morten , Böhm, Michael , DeMets, David L , Chopra, Vijay K , Kosiborod, Mikhail N , Diez, Mirta , Køber, Lars , Bengtsson, Olof , Bělohlávek, Jan , Desai, Akshay S , Merkely, Béla , Sabatine, Marc S , Martinez, Felipe A , Katova, Tzvetana , Nicolau, Jose C , de Boer, Rudolf A , Ljungman, Charlotta E.A , Sjöstrand, Mikaela , Ponikowski, Piotr , Docherty, Kieran F , Ge, Junbo , Chiang, Chern-En , Verma, Subodh

in Aged / Antidiabetics / Benzhydryl Compounds - adverse effects / Benzhydryl Compounds - therapeutic use / Cardiology and Cardiovascular Disease / Cardiovascular Agents - therapeutic use / Cardiovascular Diseases - mortality / Clinical outcomes / Clinical trials / Combined Modality Therapy / Congestive heart failure / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - complications / Diabetes Mellitus, Type 2 - drug therapy / Drug dosages / Drug therapy / Drug Therapy, Combination / Ejection fraction / Evidence-based medicine / Female / Glucosides - adverse effects / Glucosides - therapeutic use / Glycated Hemoglobin A - analysis / Heart failure / Heart Failure - complications / Heart Failure - drug therapy / Hemoglobin / Hospitalization / Humans / Hypoglycemia / Intravenous administration / Kaplan-Meier Estimate / Kardiologi och kardiovaskulära sjukdomar / Male / Middle Aged / Patient safety / Renal function / Sodium / Sodium-glucose cotransporter / Sodium-Glucose Transporter 2 Inhibitors - adverse effects / Sodium-Glucose Transporter 2 Inhibitors - therapeutic use / Stroke Volume - drug effects / Ventricular Dysfunction, Left - complications / Ventricular Dysfunction, Left - drug therapy

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2019

Confirm

Do you wish to request the book?

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Inzucchi, Silvio E,

Kitakaze, Masafumi,

Langkilde, Anna-Maria,

Howlett, Jonathan G,

Dukát, Andrej,

O’Meara, Eileen,

Jhund, Pardeep S,

Tereshchenko, Sergey,

Drozdz, Jaroslaw,

McMurray, John J.V,

Held, Claes,

Vinh, Pham N,

Petrie, Mark C,

Anand, Inder S,

Solomon, Scott D,

Schou, Morten,

Böhm, Michael,

DeMets, David L,

Chopra, Vijay K,

Kosiborod, Mikhail N,

Diez, Mirta,

Køber, Lars,

Bengtsson, Olof,

Bělohlávek, Jan,

Desai, Akshay S,

Merkely, Béla,

Sabatine, Marc S,

Martinez, Felipe A,

Katova, Tzvetana,

Nicolau, Jose C,

de Boer, Rudolf A,

Ljungman, Charlotta E.A,

Sjöstrand, Mikaela,

Ponikowski, Piotr,

Docherty, Kieran F,

Ge, Junbo,

Chiang, Chern-En,

Verma, Subodh

2019

Overview

In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death was lower among those who received dapagliflozin, regardless of the presence or absence of diabetes.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Aged

/ Antidiabetics

/ Benzhydryl Compounds - adverse effects

/ Benzhydryl Compounds - therapeutic use

/ Cardiology and Cardiovascular Disease

/ Cardiovascular Agents - therapeutic use

/ Cardiovascular Diseases - mortality